Peter Shadday becomes CEO as company is moving into a commercial-stage company, increasingly focused on U.S. market opportunitiesDr. Sabine ...

From my colleague Allison DeAngelis: A new cancer treatment developed by ITM Isotope Technologies Munich SE has succeeded in a Phase 3 trial, setting the stage for a competitor to Novartis ...

Turning to ITM, the Munich start-up said the infusion of new ... neuroendocrine tumours (GEP-NETs), a potential rival to Novartis’ Lutathera (lutetium [177Lu] oxodotreotide), and expand its ...

Oxford-based Blue Earth is developing a pair of radioligand therapeutics (RLTs) for prostate cancer, which both target PSMA - making them potential rivals to Novartis' already approved Pluvicto ...

Novartis buys Blackstone's Anthos for up to ... sees no big acquisitions in near future January 14, 2025 Leaders Bayern Munich should have scored several more goals in their 1-0 Bundesliga win ...

ITM, which is short for Isotope Technologies Munich, plans to present full trial data at an ... an approved radiopharmaceutical sold by Novartis. In an interview last June, former ITM CEO Steffen ...

Department of Medicine I, LMU University Hospital, Ludwig Maximillian University of Munich, Germany (S.K.S., U.G., S.M., S.K.). Department of Cardiology, Angiology ...

For instance, Novartis’ $1 billion acquisition of Massachusetts-based ... These are areas in which ITM has been leading for 20 years: we have two manufacturing sites in the Munich area and are the ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. Now, the rising class of bispecifics opened up an opportunity for the Swiss pharma to reenter the space ...